PTCT Q3 2025 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$6B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$211M+7.2% YoY

Gross Profit

$95M45.1% margin

Operating Income

$3M1.4% margin

Net Income

$16M7.5% margin

EPS (Diluted)

$0.20

QoQ Revenue Growth

+18.0%

Cash Flow

Operating Cash Flow

-$66M

Free Cash Flow

-$70M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$2.6B

Total Liabilities

$2.8B

Stockholders' Equity

-$156M

Cash & Equivalents

$673M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$211M	$197M	+7.2%
Gross Profit	$95M	$186M	-48.9%
Operating Income	$3M	-$55M	+105.5%
Net Income	$16M	-$107M	+114.9%

Revenue Segments

Product

$131M62%

Royalty

$71M34%

Collaboration and License Revenue

$9M4%

Geographic Segments

Non-US

$75M57%

UNITED STATES

$56M43%